Spectral AI’s DeepView™ System Showcased at the 2026 American College of Emergency Physicians (ACEP) Scientific Assembly 

Spectral AI (Nasdaq: MDAI) showcased its DeepView burn assessment system at the ACEP Scientific Assembly, held October 5–8, 2026, in Chicago.

Rhea-AI Summary

Spectral AI (Nasdaq: MDAI) showcased its DeepView burn assessment system at the ACEP Scientific Assembly, held October 5–8, 2026, in Chicago.

The event drew an estimated 7,000 attendees. DeepView is a non-invasive device that combines imaging and artificial intelligence to assess burn wounds’ healing potential. It received FDA De Novo classification in May 2026. The company identified emergency care as a priority market for commercialization and used the assembly to engage with emergency department decision makers.

Key Terms

fda-cleared, de novo classification, ukca authorization, multispectral imaging

4 terms

fda-cleared regulatory

"showcased its FDA-cleared DeepView™ System for Burn Indication"

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

de novo classification regulatory

"granted De Novo Classification by the U.S. Food and Drug Administration"

A de novo classification is a regulatory pathway that lets a novel medical device without an existing equivalent be reviewed and approved as low-to-moderate risk so it can legally enter the market. For investors, it matters because it can unlock a faster, clearer route to sales and competition protection for a new product — like getting a brand-new grocery item its own shelf space rather than forcing it to fit an existing category.

ukca authorization regulatory

"received its initial UKCA (UK Conformity Assessed) authorization"

UKCA authorization is the formal permission or marking that shows a product meets the United Kingdom’s safety, health and regulatory rules for sale in Great Britain. Think of it as a passport or safety sticker that proves a product has passed required checks. It matters to investors because lacking UKCA approval can block sales, add compliance costs, delay launches, or force changes in supply chains, any of which can affect revenue and valuation.

multispectral imaging technical

"combines multispectral imaging with a proprietary AI algorithm"

Multispectral imaging is a way of taking pictures that capture light across several distinct bands, including wavelengths the human eye cannot see, to reveal material properties or features hidden in ordinary photos. For investors, this technology can signal improved product capabilities, more accurate testing or monitoring, and new market opportunities or cost savings for companies that use it, making it a factor in competitive advantage and capital allocation decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DALLAS, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today highlighted its participation at the 2026 American College of Emergency Physicians (ACEP) Scientific Assembly, held October 5-8 in Chicago, IL. 

The Company showcased its FDA-cleared DeepView™ System for Burn Indication at this year’s Assembly. Widely recognized as the world’s largest emergency medicine conference, the event drew an estimated 7,000 attendees.  

“Having the DeepView System on display at this year’s ACEP Scientific Assembly provided our team a valuable opportunity to engage directly with emergency department decision makers, discuss their wound care assessment challenges, and introduce the DeepView System’s potential to support timely and accurate treatment decisions,” said Vincent Capone, Chief Executive Officer.

Mr. Capone continued, “Emergency care represents a priority market for our commercialization initiatives. Many emergency departments lack ready access to specialized burn expertise, creating a need for tools that support timely, informed treatment decisions. We believe integrating the DeepView System into emergency care workflows will help bridge that gap and provide valuable information to support timely, informed treatment decisions that can improve patient outcomes.”

Through continuing education, research, public education, and advocacy, ACEP advances emergency care on behalf of its 40,000 emergency physician members, and the more than 150 million people they treat on an annual basis.  

About the DeepView™ System

Spectral AI's DeepView System is a non-invasive, predictive medical device that combines multispectral imaging with a proprietary AI algorithm to assess the healing potential of areas within burn wounds. It was granted De Novo Classification by the U.S. Food and Drug Administration in May 2026 and received its initial UKCA (UK Conformity Assessed) authorization in the United Kingdom in February 2024. The DeepView System provides physicians with an immediate, data-driven assessment of whether areas within burn wounds are unlikely to heal within 21 days and may require significant medical intervention, enabling earlier and more informed treatment decisions. The image acquisition takes 0.2 seconds, and all image processing and AI model classification takes approximately 20 to 25 seconds. The DeepView System is trained and tested against a proprietary and clinically validated database of over 340 billion pixels of burn wound image data.

About Spectral AI

Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown^®” with its DeepView System. The DeepView System is a predictive diagnostic device that offers physicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal to exceed the current standard of care, the DeepView System provides fast and accurate treatment insights to improve patient outcomes and reduce healthcare costs. For more information about the DeepView System, visit www.spectral-ai.com.

The Company’s contract with the Biomedical Advanced Research and Development Authority (“BARDA”) is held and performed through its wholly owned subsidiary, Spectral MD. References to the contract, associated awards, related revenue, business opportunities, obligations, and other relevant factors should be understood to refer to Spectral MD as the contracting party unless otherwise indicated.

Forward-Looking Statements

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements. 

Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the US Securities and Exchange Commission, including the Company’s Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. 

Investors:
The Equity Group
Devin Sullivan	Conor Rodriguez
Managing Director	Associate
Devin.Sullivan@theequitygroup.com	Conor.Rodriguez@theequitygroup.com